Top

Published in:

Open Access 01-12-2016 | Laboratory Investigation

Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas

Authors: M. Bujko, P. Kober, N. Rusetska, M. Wakuła, K. Goryca, E. Grecka, E. Matyja, J. Neska, T. Mandat, W. Bonicki, J. A. Siedlecki

Published in: Journal of Neuro-Oncology | Issue 3/2016

Abstract

DLC1 encodes GTPase-activating protein with a well-documented tumor suppressor activity. This gene is downregulated in various tumors through aberrant promoter hypermethylation. Five different DLC1 isoforms can be transcribed from alternative promoters. Tumor-related DNA methylation of the DLC1 isoform 1 alternative promoter was identified as being hypermethylated in meningiomas in genome-wide DNA methylation profiling. We determined the methylation pattern of this region in 50 meningioma FFPE samples and sections of 6 normal meninges, with targeted bisulfite sequencing. All histopathological subtypes of meningiomas showed similar and significant increase of DNA methylation levels. High DNA methylation was associated with lack of DLC1 protein expression in meningiomas as determined by immunohistochemistry. mRNA expression levels of 5 isoforms of DLC1 transcript were measured in an additional series of meningiomas and normal meninges. The DLC1 isoform 1 was found as the most expressed in normal control tissue and was significantly downregulated in meningiomas. Transfection of KT21 meningioma cell line with shRNA targeting DLC1 isoform 1 resulted in increased activation of RHO-GTPases assessed with pull-down assay, enhanced cell migration observed in scratch assay as well as slight increase of cell metabolism determind by MTT test. Results indicate that isoform 1 represents the main pool of DLC1 protein in meninges and its downregulation in meningiomas is associated with hypermethylation of CpG dinucleotides within the corresponding promoter region. This isoform is functional GAP protein and tumor suppressor and targeting of its expression results in the increase of DLC1 related cell processes: RHO activation and cell migration.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral

Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379–391CrossRefPubMed

Braun AC, Olayioye MA (2015) Rho regulation: DLC proteins in space and time. Cell Signal 27:1643–1651CrossRefPubMed

Liao YC, Lo SH (2008) Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 40:843–847CrossRefPubMed

Barras D, Widmann C (2014) GAP-independent functions of DLC1 in metastasis. Cancer Metastasis Rev 33:1–14CrossRef

Xue Y-Z, Wu T-L, Wu Y-M, Sheng Y-Y, Wei Z-Q, Lu Y-F, Yu L-H, Li J-P, Li Z-S (2013) DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumour Biol 34:2857–2861CrossRefPubMed

Ko FCF, Yeung YS, Wong CM, Chan LK, Poon RTP, Ng IOL, Yam JWP (2010) Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int 30:139–148CrossRefPubMed

Sabbir MG, Wigle N, Loewen S, Gu Y, Buse C, Hicks GG, Mowat MRA (2010) Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform. BMC Biol 8:17CrossRefPubMedPubMedCentral

Low JSW, Tao Q, Ng KM et al (2011) A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene 30:1923–1935CrossRefPubMedPubMedCentral

10.

Hankins GR, Sasaki T, Lieu A-S, Saulle D, Karimi K, Li JZ, Helm GA (2008) Identification of the deleted in liver cancer 1 gene, Dlc1, as a candidate meningioma tumor suppressor. Neurosurgery 63:771–781CrossRefPubMed

11.

Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Özduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yılmaz B, Conor Gr MG (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080CrossRefPubMedPubMedCentral

12.

Brastianos PK, Horowitz PM, Santagata S et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289CrossRefPubMedPubMedCentral

13.

O’Leary NA, Wright MW, Brister JR et al (2015) Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res 44:733–745CrossRef

14.

Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-cabrero D, Beck S (2013) Gene expression A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450k DNA methylation data. Bioinformatics 29:189–196CrossRefPubMed

15.

Pfister C, Tatabiga MS, Roser F (2011) Selection of suitable reference genes for quantitative real-time polymerase chain reaction in human meningiomas and arachnoidea. BMC Res Notes 4:275CrossRefPubMedPubMedCentral

16.

Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, Miyaki M (1989) Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 64:2243–2249CrossRefPubMed

17.

Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC (2006) Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 12:1412–1419CrossRefPubMed

18.

Feng X, Ren C, Zhou W et al (2013) Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma. Mol Carcinog 870:1–13

19.

Dai Z, Jin Y (2013) Promoter methylation of the DLC-1 gene and its inhibitory effect on human colon cancer. Oncol Rep 30:1511–1517PubMed

20.

Zhou X, Thorgeirsson SS, Popescu NC (2004) Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 23:1308–1313CrossRefPubMed

21.

Yuan B-Z, Jefferson AM, Millecchia L, Popescu NC, Reynolds SH (2007) Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 313:3868–3880CrossRefPubMed

22.

Tripathi V, Popescu NC, Zimonjic DB (2012) DLC1 interaction with -Catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity. Mol Cell Biol 32:2145–2159CrossRefPubMedPubMedCentral

23.

Marx A, Kahan T, Simon I (2013) Integrative analysis of methylome and transcriptome reveals the importance of unmethylated CpGs in non-CpG island gene activation. Biomed Res Int 2013:785731CrossRefPubMedPubMedCentral

24.

Han H, Cortez CC, Yang X, Nichols PW, Jones PA., Liang G (2011) DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 20:4299–4310CrossRefPubMedPubMedCentral

25.

Lin B, Wang Y, Wang Z et al (2014) Uncovering the rare variants of DLC1 isoform 1 and their functional effects in a chinese sporadic congenital heart disease cohort. PLoS One 9:e90215CrossRefPubMedPubMedCentral

26.

Wang X, Gong Y, Wang D et al (2012) Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PLoS One 7:1–10

27.

Carlos J, Gómez I, Orgueira AM (2014) An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation. Front Oncol 4:1–12

28.

Landry JR, Mager DL, Wilhelm BT (2003) Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 19:640–648CrossRefPubMed

29.

Blackburn J, Roden DL, Ng R, Wu J, Bosman A, Epstein RJ (2015) Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter. Mol Carcinog. doi:10.1002/mc.22441 PubMedPubMedCentral

Title: Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas
Authors: M. Bujko
P. Kober
N. Rusetska
M. Wakuła
K. Goryca
E. Grecka
E. Matyja
J. Neska
T. Mandat
W. Bonicki
J. A. Siedlecki
Publication date: 01-12-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2261-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

A case-matched study of stereotactic radiosurgery for patients with brain metastases: comparing treatment results for those with versus without neurological symptoms

Surgical management of posterior fossa metastases

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma

Occupational exposure to metals and risk of meningioma: a multinational case-control study

Molecular and histologic characteristics of pseudoprogression in diffuse gliomas

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma